Welcome to our dedicated page for HINTO ENERGY news (Ticker: HENI), a resource for investors and traders seeking the latest updates and insights on HINTO ENERGY stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect HINTO ENERGY's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of HINTO ENERGY's position in the market.
Hinto Energy, Inc. (OTC:HENI) announced the acquisition of assets related to a novel treatment for fibromyalgia, JF-100, from JF BioPharma Inc. The agreement, dated March 6, 2023, involves the issuance of 1,000,000 shares of preferred C stock. JF-100 aims to address three root causes of fibromyalgia by modulating the endocannabinoid system, reducing oxidative stress, and enhancing mitochondrial energy production. A Phase 2 clinical study is planned to establish optimal dosing, leading to a subsequent Phase 3 trial. Global prevalence of fibromyalgia affects 4% of the population, predominantly women aged 20-50.
Hinto Energy, Inc. (OTCQB:HENI) announced a significant change of control due to the sale of Series A Preferred shares from Synergy Management Group LLC to JF Biopharma, Inc. This transaction, expected to close by month-end March 2023, gives JF Biopharma voting control over Hinto Energy. New management has been appointed, including Jason Frankovich as Director and David Conkling as VP of Business Development. The company aims to shift its focus towards biotechnology, planning multiple acquisitions. A name and symbol change will also be submitted to FINRA soon.
FAQ
What is the current stock price of HINTO ENERGY (HENI)?
What is the market cap of HINTO ENERGY (HENI)?
